Poster presented at the 2022 European Society of Gene & Cell Therapy Congress in Edinburgh.Also available: https://shs.hal.science/halshs-03901269v
Genes, cells, and tissues based medicinal products are specifically regulated as Advanced Therapy Me...
Advanced therapy medicinal products (ATMPs) have a massive potential to address existing unmet medic...
The new Regulation (EU) No. 536/2014 for clinical trials of medicinal products for human is part of ...
The European Health Technology Assessment (HTA) regulation was adopted at the end of 2021. HTA is “a...
Poster presented at the 2022 Conference of the European Association of Health Law (EAHL) in Ghent.Al...
Poster presented at the 2022 European Society of Gene & Cell Therapy Congress in Edinburgh.Also avai...
Poster presented at the 2022 European Society of Gene & Cell Therapy Congress in Edinburgh.Also avai...
Health technology assessment is a key tool for ensuring healthcare quality, accessibility, and susta...
Poster presented at the 2022 European Society of Gene & Cell Therapy Congress in Edinburgh.Also avai...
Poster presented at the 2022 Conference of the European Association of Health Law (EAHL) in Ghent.Al...
Even for centrally approved products, each European country is responsible for the effective nationa...
Poster presented at the 2022 Conference of the European Association of Health Law (EAHL) in Ghent.Al...
Poster presented at the 2022 Conference of the European Association of Health Law (EAHL) in Ghent
The regulatory evolution of medical technologies in the European Union offers a unique perspective w...
The European Union has introduced stricter provisions for medical devices under the new Medical Devi...
Genes, cells, and tissues based medicinal products are specifically regulated as Advanced Therapy Me...
Advanced therapy medicinal products (ATMPs) have a massive potential to address existing unmet medic...
The new Regulation (EU) No. 536/2014 for clinical trials of medicinal products for human is part of ...
The European Health Technology Assessment (HTA) regulation was adopted at the end of 2021. HTA is “a...
Poster presented at the 2022 Conference of the European Association of Health Law (EAHL) in Ghent.Al...
Poster presented at the 2022 European Society of Gene & Cell Therapy Congress in Edinburgh.Also avai...
Poster presented at the 2022 European Society of Gene & Cell Therapy Congress in Edinburgh.Also avai...
Health technology assessment is a key tool for ensuring healthcare quality, accessibility, and susta...
Poster presented at the 2022 European Society of Gene & Cell Therapy Congress in Edinburgh.Also avai...
Poster presented at the 2022 Conference of the European Association of Health Law (EAHL) in Ghent.Al...
Even for centrally approved products, each European country is responsible for the effective nationa...
Poster presented at the 2022 Conference of the European Association of Health Law (EAHL) in Ghent.Al...
Poster presented at the 2022 Conference of the European Association of Health Law (EAHL) in Ghent
The regulatory evolution of medical technologies in the European Union offers a unique perspective w...
The European Union has introduced stricter provisions for medical devices under the new Medical Devi...
Genes, cells, and tissues based medicinal products are specifically regulated as Advanced Therapy Me...
Advanced therapy medicinal products (ATMPs) have a massive potential to address existing unmet medic...
The new Regulation (EU) No. 536/2014 for clinical trials of medicinal products for human is part of ...
DOI
Add to ORKG